A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARAGON-HF
- Sponsors Novartis
- 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.